跳到正文
原文
Medical Xpress·· 2026-10-09AI 评分52

天然化合物 argyrin B 在实验室与小鼠模型中抑制艰难梭菌,对健康肠道菌群影响较小

Natural compound shows promise against C. difficile while largely sparing healthy gut bacteria

AI 导读

德国汉诺威医学院、萨尔大学医院和亥姆霍兹萨尔药物研究所的研究团队报告,天然化合物 argyrin B 在实验室实验和艰难梭菌感染小鼠模型中显著降低细菌载量,结果发表于 npj Antimicrobials and Resistance。该化合物口服后很少进入小鼠血液,主要停留在大肠,对肠道有益微生物几乎无影响。研究者称后续将确定达到最大效力所需的最佳剂量,并在相应模型中测试其对复发感染的效力。

正文
blue stick-shaped bacteria
Electron-microscope image of Clostridioides difficile. Credit: HZI/Manfred Rohde

The pathogen Clostridioides difficile (C. difficile) is naturally present in the intestines of many people. When present in small numbers, it usually causes no symptoms. Treatment with broad-spectrum antibiotics can severely disrupt the balance of the healthy gut microbiome, allowing the bacterium to multiply unchecked. The result is acute intestinal inflammation, which can also become chronic. Such infections with C. difficile (CDI) are among the leading causes of antibiotic-associated diarrhea. Since the bacteria release toxins that can lead to dangerous, sometimes life-threatening intestinal inflammation with high relapse rates, new therapeutic approaches are urgently needed.

Treatment with broad-spectrum antibiotics often leads to side effects, as it affects not only the pathogens but also the "good" bacteria in the gut. A research team from Hannover Medical School (MHH), Saarland University Hospital (UKS) and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now demonstrated that the natural compound argyrin B is highly effective against the pathogen Clostridioides difficile while largely sparing the beneficial gut microbiome. The researchers published their findings in the journal npj Antimicrobials and Resistance.

"We were able to show that the natural compound argyrin B is highly effective against CDI, both in laboratory experiments and in a mouse model of the infection, where it significantly reduces the bacterial load," says Dr. Jennifer Herrmann, senior scientist in the Microbial Natural Products department at HIPS.

"An antibacterial target of the argyrins had previously been identified and characterized in the notorious hospital-acquired pathogen Pseudomonas aeruginosa. Now we have been able to show that argyrin B also acts on this target in C. difficile and exhibits particularly high efficacy in doing so.

"In contrast, the argyrins have virtually no effect on the beneficial microorganisms in our digestive tract. The gut microbiome could therefore be spared during treatment with argyrin and restored to a healthy state more quickly."

The argyrins were identified in soil-dwelling myxobacteria. These bacteria use such natural compounds, among other things, to hunt other microorganisms and exploit them as a food source. However, before argyrins can be used as medications, not only their efficacy but also the pharmaceutical properties of this class of substances must be evaluated.

In doing so, the researchers discovered that argyrin B barely enters the bloodstream of mice when administered orally. Instead, it remains largely in the large intestine. This also helps prevent unwanted side effects in other parts of the body. Argyrin B therefore represents a potentially well-tolerated therapeutic approach against CDI.

Fecal microbiota transfer (commonly known as a stool transplant) is often used to treat CDI in cases of multiple relapses. However, this procedure is complex and unpleasant for many patients. A new active ingredient based on argyrin could help reduce the risk of further disruptions to the gut microbiota, infections and relapses that would otherwise require treatment via microbiota transfer.

In follow-up studies, the researchers aim to determine the optimal dosage of argyrin B required to achieve maximum efficacy. They also plan to use appropriate models to test how effective this natural compound is against recurrent infections.

More information

Sari Rasheed et al, Argyrin B exhibits potent therapeutic efficacy in a Clostridioides difficile-infection mouse model while preserving microbiota functionality, npj Antimicrobials and Resistance (2026). DOI: 10.1038/s44259-026-00248-x

Provided by Helmholtz Centre for Infection Research

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Natural compound shows promise against C. difficile while largely sparing healthy gut bacteria (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-natural-compound-difficile-largely-healthy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com